98%
921
2 minutes
20
Crystallizing soluble amyloid oligomers (AOs) presents a major challenge in studying disease-related mutations associated with amyloid diseases. The G37R mutation in superoxide dismutase 1 (SOD1) is linked to early onset amyotrophic lateral sclerosis (ALS), yet its toxic mechanism remains unclear. The transient nature and low solubility of AOs often complicate the production of high-quality crystals required for X-ray crystallography (XRC) analysis. To address these challenges, we employ native ion mobility spectrometry-mass spectrometry (IMS-MS) to screen SOD1 peptides and examine correlations between structural features that reflect AO stability, their sequence length, and specific mutations. In particular, previous studies showed that the P28K mutation in SOD1(28-38) enhances solubility, thus allowing the capture of AO corkscrew structures for both SOD1(28-38) and SOD1(28-38). Building on these findings, we expanded our screening to include SOD1 peptides with longer sequences, identifying structural features in IMS-MS spectra that correlate with improved crystallization potential. This approach enabled us to distinguish the stabilizing effects of G37R from those of P28K, culminating in the successful determination of the first crystal structure of the SOD1 corkscrew containing the native proline.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jacs.5c00656 | DOI Listing |
PLoS One
September 2025
Department of Chemistry, University of California, Irvine, California, United States of America.
Anti-Aβ antibodies are important tools for identifying structural features of aggregates of the Aβ peptide and are used in many aspects of Alzheimer's disease (AD) research. Our laboratory recently reported the generation of a polyclonal antibody, pAb2AT-L, that is moderately selective for oligomeric Aβ over monomeric and fibrillar Aβ and recognizes the diffuse peripheries of Aβ plaques in AD brain tissue but does not recognize the dense fibrillar plaque cores. This antibody was generated against 2AT-L, a structurally defined Aβ oligomer mimic composed of three Aβ-derived β-hairpins arranged in a triangular fashion and covalently stabilized with three disulfide bonds.
View Article and Find Full Text PDFCurr Neuropharmacol
August 2025
Department of Neurology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
Introduction: Amyloid-beta-targeting monoclonal antibodies (mAbs) for Alzheimer's disease frequently induce amyloid-related imaging abnormalities with hemorrhage (ARIA-H), yet systematic comparisons of ARIA-H incidence across therapeutic agents remain limited. Post-approval research prioritizes dosing over mechanism, leaving unresolved whether ARIA-H variations originate from intrinsic mAb properties. We address two gaps: comparative ARIA-H risk stratification among clinically available/investigational mAbs, and elucidation of structural/functional features influencing ARIA-H susceptibility.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
September 2025
Department of Biology and Chemistry, Paul Scherrer Institute, Forschungsstrasse 111, Villigen, PSI, 5232, Switzerland.
LL-37 and its variants with amphiphilic structure can modulate amyloid-β (Aβ) fibril formation, but the detailed mechanism behind it is still unclear. By using four different peptides (LL-37, LL-37, LL-37, LL-37), we found these peptides affect Aβ40 aggregation differently. Nanoscale analysis showed that all LL-37 peptides form hetero-oligomers and nanoclusters with Aβ40, but LL-37 and LL-37, which exhibit the strongest inhibition of Aβ fibrillation, form more hetero-oligomers and smaller nanoclusters.
View Article and Find Full Text PDFSpectrochim Acta A Mol Biomol Spectrosc
August 2025
Department of Biochemistry and Biophysics, Stockholm University, Sweden. Electronic address:
Aggregation of the amyloid-β peptide (Aβ) characterises and probably causes Alzheimer's disease. While lipid-mediated Aβ aggregation has been extensively studied for the 40-residue variant Aβ40, the interaction of the 42-residue variant Aβ42 with membranes has received less attention. Our time-resolved infrared spectra demonstrate that Aβ42 oligomers preserve their β-sheet structure in aqueous solution also in a membrane-mimicking environment consisting of either 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (POPC, zwitterionic) or 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'racglycerol) (POPG, anionic) vesicles.
View Article and Find Full Text PDFACS Chem Neurosci
September 2025
Graduate School of Science, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe 657-8501, Japan.
The development of drugs for Alzheimer's disease, which accounts for over half of all dementia cases, remains challenging. Amyloid β 1-42 (Aβ42) is widely recognized for its deposition in the brains of patients with Alzheimer's disease. Furthermore, Aβ42-induced cell toxicity likely plays a role in disease onset.
View Article and Find Full Text PDF